What We're Reading: Page
Industry reads hand-picked by our editors
Nov 17, 2023
-
Investor’s Business Daily
Biotech Stocks: The Race For An Alzheimer’s Cure Takes Off
-
ScienceNews
Why a popular breast cancer drug may be less effective for some Africans
-
Reuters
Manufacturer Lonza says it will not fill obesity drug syringes
Nov 16, 2023
-
Fierce Pharma
Novo Nordisk fights back at Lilly with Wegovy combo trial against Zepbound in obesity
-
Stat
FDA’s latest reorganization puts a new emphasis on its investigations
-
Bloomberg
Sanofi Taps Adviser for OTC Spinoff as Buyout Firms Circle
-
The Boston Globe
The ‘bump factor’ returns to Kendall Square
Nov 15, 2023
-
Reuters
Drugmaker Mallinckrodt emerges from bankruptcy
-
The Boston Globe
EMD Serono plans to join biopharma cluster in Boston’s Seaport
-
KFF Health News
Biden Administration’s Limit on Drug Industry Middlemen Backfires, Pharmacists Say
-
NPR
Roland Pattillo protected Henrietta Lacks’ memory. He died leaving that legacy
Nov 14, 2023
-
Health Affairs
What’s The Worst That Could Happen? A Toothless FDA
-
Fierce Biotech
Hepatitis B drug developers chart slow progress, just like in hep C
-
Regulatory Focus
FDA announces OPQ reorganization to alleviate ‘long-standing pain points’
-
The Transmitter
Making cancer nervous
Nov 13, 2023
Nov 10, 2023
-
Investor’s Business Daily
Amylyx Stock Crashes As Patients Drop Off ALS Drug, Relyvrio
-
Axios
“I’ve never seen anything like this”: High demand fuels drug shortages
-
MIT Technology Review
How open-source drug discovery could help us in the next pandemic
Previous
